biostudies-literatureTosun DNIH/NIANational Institute of Neurological Disorders and StrokeNIA NIH HHSNINDS NIH HHSNational Institutes of HealthNIH HHS5114-5131https://www.ebi.ac.uk/biostudies/studies/S-EPMC11350010biostudies-literatureUnknown20(8)<h4>Introduction</h4>Alzheimer's disease (AD) pathology is defined by β-amyloid (Aβ) plaques and neurofibrillary tau, but Lewy bodies (LBs; 𝛼-synuclein aggregates) are a common co-pathology for which effective biomarkers are needed.<h4>Methods</h4>A validated α-synuclein Seed Amplification Assay (SAA) was used on recent cerebrospinal fluid (CSF) samples from 1638 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants, 78 with LB-pathology confirmation at autopsy. We compared SAA outcomes with neuropathology, Aβ and tau biomarkers, risk-factors, genetics, and cognitive trajectories.<h4>Results</h4>SAA showed 79% sensitivity and 97% specificity for LB pathology, with superior performance in identifying neocortical (100%) compared to limbic (57%) and amygdala-predominant (60%) LB-paAlzheimer's & dementia : the journal of the Alzheimer's AssociationA cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function.PMC11350010U19 AG024904AG000546U01 AG024904Saykin AJSingleton ABThropp PMacLeod KBlauwendraat CMcEvoy SAlzheimer's Disease Neuroimaging InitiativeTosun DHausle ZWeiner MWLamoureux JIwaki HLee EBPerrin RJShaw LMNalls MLebovitz RfalseA cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function.<h4>Introduction</h4>Alzheimer's disease (AD) pathology is defined by β-amyloid (Aβ) plaques and neurofibrillary tau, but Lewy bodies (LBs; 𝛼-synuclein aggregates) are a common co-pathology for which effective biomarkers are needed.<h4>Methods</h4>A validated α-synuclein Seed Amplification Assay (SAA) was used on recent cerebrospinal fluid (CSF) samples from 1638 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants, 78 with LB-pathology confirmation at autopsy. We compared SAA outcomes with neuropathology, Aβ and tau biomarkers, risk-factors, genetics, and cognitive trajectories.<h4>Results</h4>SAA showed 79% sensitivity and 97% specificity for LB pathology, with superior performance in identifying neocortical (100%) compared to limbic (57%) and amygdala-predominant (60%) LB-pa2024-01-01T00:00:00Z2024 Aug2025-04-19T01:43:33.35Z2025-04-19T01:43:33.35ZS-EPMC113500103877082910.1002/alz.13858